Aurobindo Pharma
Aurobindo Pharma
Shareholder Return: 3-year average, Sales Growth: 3-year Compounded Annual Growth Rate, Return On Equity: 3-year Return on Equity.
At a Glance
-
Shareholder Return1003%
-
Sales Growth38%
-
Return on Equity28 %
Why Super 50
The company, which focuses on the formulations business, has surprised investors and analysts every quarter by delivering results in line with or better than market expectations. It has fared better than its peers in getting US FDA approvals for new products. Even as its market in the US is growing, Europe is in the company's radar as the next growth driver.
